Cencora

(New York Stock Exchange)
Back to all articles
Bullish +75

Here’s Why Cencora (COR) Shares Rose 8% in Q4

AI-generated analysis

πŸ“ˆ Cencora (COR) shares rose 8% following positive coverage from TimesSquare Capital Management in its Q4 2025 investor letter.

πŸ₯ The fund identified Cencora as a preferred health care stock due to its role in pharmaceutical sourcing and distribution.

πŸ’° Fiscal Q4 earnings beat consensus estimates, with U.S. strength offsetting misses in international markets.

🀝 Management is exploring strategic alternatives for the animal health and non-core portions of its PharmaLex business.

πŸ“Š As of March 19, 2026, Cencora closed at $331.74 with a market cap of approximately $64.5 billion.

πŸ”„ Hedge fund holdings of Cencora increased slightly from 59 to 61 portfolios in the fourth quarter of 2025.

πŸ“ˆ Fiscal Q1 2026 revenue grew 5.5% year-over-year, reaching $85.9 billion across all segments.

🧠 While acknowledged as a potential investment, the analyst notes AI stocks currently offer greater upside with less downside risk.

βš–οΈ The TimesSquare U.S. Focus Growth Strategy returned 14.84% gross in 2025 compared to an 8.66% index return.

🌍 Global markets ended Q4 positively, driven by Europe and Emerging Markets, though geopolitical concerns persist.

πŸ“‰ The strategy saw a decline of -3.55% in Q4 while the Russell Midcap Growth Index dropped -3.70%.

🧾 Cencora is not currently on the list of 40 most popular stocks for 2026 according to the firm's database.

Bullish Signals
  • Cencora shares gained 8% following the release of the investor letter, signaling market confidence.
  • Fiscal fourth-quarter earnings outpaced consensus estimates, demonstrating resilient operational performance.
  • Consolidated revenue increased 5.5% year-over-year to $85.9 billion in Q1 fiscal 2026, driven by solid growth in both reportable segments.
  • Hedge fund interest remains strong with 61 portfolios holding the stock at the end of the fourth quarter, up from 59 in the previous quarter.
  • The company's strategic consideration of alternatives for non-core parts of its PharmaLex business suggests active management focused on core value drivers.
Risk Factors
  • Although fiscal Q4 earnings outpaced estimates, the strength was offset by a miss in international business, indicating geographic concentration risk.
  • The management team is considering strategic alternatives for the animal health and non-core parts of its PharmaLex business, which could lead to asset sales or restructuring uncertainty.
  • Cencora Inc. is not included in the fund's list of 40 Most Popular Stocks Ahead of 2026, suggesting relative lack of conviction compared to peers.
  • The investment manager explicitly believes certain AI stocks offer greater upside potential and carry less downside risk than Cencora Inc., signaling a shift in capital allocation away from the company.
  • Cencora Inc. was absent from the fund's top holdings despite being a preferred healthcare name, implying it may fall below their investment threshold for 2026.
  • One-month return of Cencora Inc. was negative at -8.13%, showing recent price weakness that contrasts with the stock gaining 24.05% over the past 52 weeks.
Full Analysis
TimesSquare Capital Management released its fourth-quarter 2025 investor letter for the U.S. Focus Growth Strategy, which noted that the strategy returned -3.55% gross and -3.76% net during the quarter compared to a -3.70% return for the Russell Midcap Growth Index. Over the full year of 2025, the strategy delivered a 14.84% gross return against an 8.66% gain for the index. The firm highlighted its top five holdings and specifically discussed its position in Cencora, Inc., trading under the NYSE ticker COR. According to the letter, TimesSquare Capital prefers health care stocks that offer novel therapies for unmet needs with premium pricing or specialized service providers. Cencora is classified as a pharmaceutical sourcing and distribution company, and the stock gained 8% over the period covered in the report. The letter cites specific financial data regarding Cencora, noting that its fiscal fourth-quarter earnings exceeded consensus estimates due to strength in U.S. business offsetting a miss in international operations. Management at Cencora had also announced consideration of strategic alternatives for the animal health and non-core portions of its PharmaLex business. As of March 19, 2026, Cencora shares closed at $331.74, reflecting a one-month return of -8.13% but a 52-week gain of 24.05%. The company's market capitalization is approximately $64.53 billion. Data from TimesSquare shows that 61 hedge fund portfolios held Cencora at the end of the fourth quarter, an increase from 59 portfolios in the previous quarter. Despite the positive performance and increased institutional holdings, TimesSquare Capital indicated it does not currently list Cencora among its top picks compared to certain AI stocks, which the firm believes offer greater upside potential with less downside risk. The first quarter of fiscal 2026 saw Cencora's consolidated revenue increase by 5.5% year-over-year to $85.9 billion driven by solid growth in both reportable segments. The article concludes by directing readers to additional resources on best healthcare stocks for 2026 and a broader collection of Q4 2025 investor letters, while noting the disclosure that no conflicts were present with the original publication at Insider Monkey.